Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erica K Evans

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Molecular & Cellular Oncology|September 26, 2018
Targeting kinases with precisionAlexandra K Gardino, Erica K Evans, Joseph L Kim, et al.
Blood|July 19, 2003
The amino terminal and E2F interaction domains are critical for C/EBP alpha-mediated induction of granulopoietic development of hematopoietic cellsFrancesco D'Alo', Lisa M Johansen, Erik A Nelson, et al.
Molecular and Cellular Biology|March 16, 2005
Potential autoregulation of transcription factor PU.1 by an upstream regulatory elementYutaka Okuno, Gang Huang, Frank Rosenbauer, et al.
Communications Biology|September 14, 2022
PU.1-c-Jun interaction is crucial for PU.1 function in myeloid developmentXinhui Zhao, Boris Bartholdy, Yukiya Yamamoto, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 28, 2013
Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humansErica K Evans, Richland Tester, Sharon Aslanian, et al.
Nature Medicine|December 7, 2021
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trialDaniel J DeAngelo, Deepti H Radia, Tracy I George, et al.
The Lancet. Oncology|July 3, 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trialMichael C Heinrich, Robin L Jones, Margaret von Mehren, et al.
Cancer Discovery|April 17, 2018
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven CancersVivek Subbiah, Justin F Gainor, Rami Rahal, et al.
Science Translational Medicine|November 3, 2017
A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutationsErica K Evans, Alexandra K Gardino, Joseph L Kim, et al.
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Molecular & Cellular Oncology|September 26, 2018
Targeting kinases with precisionAlexandra K Gardino, Erica K Evans, Joseph L Kim, et al.
Blood|July 19, 2003
The amino terminal and E2F interaction domains are critical for C/EBP alpha-mediated induction of granulopoietic development of hematopoietic cellsFrancesco D'Alo', Lisa M Johansen, Erik A Nelson, et al.
Molecular and Cellular Biology|March 16, 2005
Potential autoregulation of transcription factor PU.1 by an upstream regulatory elementYutaka Okuno, Gang Huang, Frank Rosenbauer, et al.
Communications Biology|September 14, 2022
PU.1-c-Jun interaction is crucial for PU.1 function in myeloid developmentXinhui Zhao, Boris Bartholdy, Yukiya Yamamoto, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 28, 2013
Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humansErica K Evans, Richland Tester, Sharon Aslanian, et al.
Nature Medicine|December 7, 2021
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trialDaniel J DeAngelo, Deepti H Radia, Tracy I George, et al.
The Lancet. Oncology|July 3, 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trialMichael C Heinrich, Robin L Jones, Margaret von Mehren, et al.
Cancer Discovery|April 17, 2018
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven CancersVivek Subbiah, Justin F Gainor, Rami Rahal, et al.
Science Translational Medicine|November 3, 2017
A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutationsErica K Evans, Alexandra K Gardino, Joseph L Kim, et al.
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
Pageof 1